Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

CAR T cells produce complete responses in T-cell malignancies

Key clinical point: Anti-CD5 chimeric antigen receptor (CAR) T cells can produce complete responses (CRs) in patients with relapsed/refractory T-cell malignancies.

Major finding: Three patients achieved a CR after CAR T-cell therapy, and one patient achieved a mixed response that deepened to a CR after transplant.

Study details: A phase 1 trial of 11 treated patients.

Disclosures: The trial is sponsored by Baylor College of Medicine. Dr. Hill reported having no conflicts of interest.


Hill L et al. ASH 2019, Abstract 199.